www.fdanews.com/articles/86810-positive-results-for-acrux-s-lead-product-in-us-phase-3-trial
POSITIVE RESULTS FOR ACRUX'S LEAD PRODUCT IN US PHASE 3 TRIAL
May 15, 2006
Acrux, the pharmaceutical company with unique technology for delivering drugs through the skin, today announced positive results in a US Phase 3 clinical trial of Evamist, its daily skin spray for prevention of symptoms associated with menopause. The trial was conducted by its US commercial partner VIVUS Inc., which will now proceed to file a marketing application with the US Food and Drug Administration (FDA) in the second half of 2006. Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=43178)